JPH3

Across TCGA pan-cancer cohorts, JPH3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of JPH3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where JPH3 RNA is repressed in tumor relative to normal tissue. In most cancer types JPH3 is over-expressed in tumor, although a few such as COAD and UCEC show the opposite, repressed pattern.

COAD, HNSC, and LUAD are the cancer types where JPH3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JPH3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	−0.475	<.001	10	view →
HNSC	All	II,III,IV	+0.416	.001	8	view →
LUAD	Female	All	+0.637	<.001	6	view →
UCEC	All	All	−0.540	<.001	6	view →
BRCA	Female	All	+0.369	<.001	6	view →
LUSC	All	All	+0.617	<.001	5	view →
THCA	All	All	+0.286	.001	5	view →
STAD	Female	All	−0.641	.004	2	view →
PAAD	Female	All	+0.570	.017	2	view →
READ	All	All	−0.563	.001	2	view →
PRAD	All	All	−0.213	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

JPH3–COAD

Open the COAD breakdown →